CAI analyst estimates
Caris Life Sciences (CAI) analyst ratings, the average price target and its range, and every firm's latest call.
CAI analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 27, 2026 | BTIG | Caris Life Sciences price target raised to $38 from $33 at BTIG | $38.00 |
| Sep 9, 2026 | UBS | Caris Life Sciences initiated with a Neutral at UBS | $28.00 |
| Aug 7, 2026 | BTIG | Caris Life Sciences price target raised to $33 from $32 at BTIG | $33.00 |
| Aug 6, 2026 | Evercore ISI | Caris Life Sciences price target raised to $26 from $25 at Evercore ISI | $26.00 |
| Jul 6, 2026 | Evercore ISI | Caris Life Sciences price target lowered to $25 from $30 at Evercore ISI | $25.00 |
| May 8, 2026 | BTIG | Caris Life Sciences price target lowered to $32 from $38 at BTIG | $32.00 |
| May 8, 2026 | Robert W. Baird | Caris Life Sciences price target lowered to $22 from $28 at Baird | $22.00 |
| Apr 10, 2026 | Piper Sandler | Caris Life Sciences initiated with a Neutral at Piper Sandler | $21.00 |
| Feb 17, 2026 | Robert W. Baird | Caris Life Sciences initiated with an Outperform at Baird | $26.00 |
| Jan 5, 2026 | Evercore ISI | Caris Life Sciences price target lowered to $38 from $40 at Evercore ISI | $38.00 |
| Dec 22, 2025 | Canaccord Genuity | Caris Life Sciences price target raised to $30 from $28 at Canaccord | $30.00 |
| Dec 2, 2025 | Canaccord Genuity | Caris Life Sciences initiated with a Hold at Canaccord | $28.00 |
| Aug 13, 2025 | BTIG | Caris Life Sciences price target raised to $45 from $38 at BTIG | $45.00 |
| Jul 13, 2025 | Guggenheim | Caris Life Sciences initiated with a Buy at Guggenheim | $32.00 |
- 10 firms rate CAI: 7 buy, 3 hold, 0 sell.
- The average price target is $28.50 from 4 analysts, from $22.00 to $38.00.
Updated 2026-11-03 00:00 UTC